Alexza Pharmaceuticals and Spanish pharmaceutical company Grupo Ferrer International have formed a partnership to register, distribute, and promote the Adasuve Staccato loxapine inhaler for the treatment of agitation in patients with schizophrenia or bipolar disorder in Europe, Commonwealth of Independent States countries, and Latin America. The deal includes a $10 … [Read more...] about Alexza teams with Grupo Ferrer on Staccato loxapine inhaler
News
Lightlake announces Phase 2 trial of nasal spray for bulimia nervosa
King's College London will be the site of Phase 2 trials of Lightlake Therapeutics's opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland to demonstrate the effectiveness of its naloxone nasal spray for the treatment of binge eating disorder in overweight and obese … [Read more...] about Lightlake announces Phase 2 trial of nasal spray for bulimia nervosa
BASF and Ineos join forces in Styrolution
Inhaler manufacturers who have been purchasing acrylonitrile butadiene styrene (ABS) for inhaler housings from either BASF or Ineos will now have a new supplier: Styrolution. Ineos's Lustran, Novodur, and Absolac brands and BASF's Terluran brand will be sold by the new company, a 50/50 joint venture of BASF and Ineos, which is headquartered in Frankfurt/Main, Germany, … [Read more...] about BASF and Ineos join forces in Styrolution
Mymetics reclaims intranasal flu vaccine that had been licensed to Solvay
Swiss vaccine developer Mymetics Corporation has reclaimed an intranasal influenza vaccine that it had licensed to Solvay prior to Solvay's acquisition by Abbott Laboratories. Solvay had conducted a Phase 1 trial that found the vaccine to be well tolerated and safe and had made a milestone payment to Mymetics before stopping work on the project. Mymetics CFO Ronald … [Read more...] about Mymetics reclaims intranasal flu vaccine that had been licensed to Solvay
Quebec is first Canadian province to offer formulary access to TOBI Podhaler
Novartis Pharmaceuticals Canada has announced that the Québec provincial government will now provide reimbursement for the TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.The company cites data from Cystic Fibrosis Canada that show about 1,200 cystic fibrosis patients residing in Québec. TOBI Podhaler … [Read more...] about Quebec is first Canadian province to offer formulary access to TOBI Podhaler
Second nasal delivery device contract for Bespak
Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that "a major global manufacturer of generic medicines" has awarded Bespak a contract for both development of its Unidose nasal drug delivery device for an undisclosed application and for manufacturing and … [Read more...] about Second nasal delivery device contract for Bespak
Teva offering assistance to Primatene Mist users
Teva Respiratory has announced that it will provide assistance to patients affected by the impending phase out of the OTC Primatene Mist epinephrine inhaler. In addition to providing educational resources, the company says that it will offer financial assistance programs and samples of its ProAir HFA albuterol and QVar HFA beclamethasone metered dose inhalers. Teva … [Read more...] about Teva offering assistance to Primatene Mist users
No safety problems for Nanotherapeutics’ nasal dry powder vaccine in Phase 1 trial
A Phase 1 clinical trial of a novel dry powder intranasal vaccine for prevention of the H5N1 influenza strain demonstrated that the product was well tolerated, and no serious adverse events occurred, according to developer Nanotherapeutics. the GelVac nasal dry powder H5N1 vaccine is delivered by a disposable single-use positive pressure intranasal inhaler that uses … [Read more...] about No safety problems for Nanotherapeutics’ nasal dry powder vaccine in Phase 1 trial
PPD agrees to be acquired for $3.9 billion
The board of directors of contract research organization PPD has approved a $3.9 billion all cash deal which will take the company private after its acquisition by the Carlyle Group and Hellman & Friedman. PPD offers formulation development and analytical services for a wide variety of OINDPs, including DPIs, MDIs, inhalation solutions, and nasal aerosols. The deal, … [Read more...] about PPD agrees to be acquired for $3.9 billion
British Pharmacopoeia adds working party for inhaled products, seeks input
According to the British Pharmacopoeia website: "The British Pharmacopoeia Commission has recently endorsed the formation of a new Working Party for Inhaled Products (IP). The remit of the Working Party will be to review the current published monographs for Inhaled Products and associated General Monographs and Supplementary Chapters." "Stakeholders are invited … [Read more...] about British Pharmacopoeia adds working party for inhaled products, seeks input